News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi to Terminate Marketing Agreement on the Oral Hypoglycemic Euglucon and the Cardiotonic Glycoside Lanirapid

April 21, 2003

Tokyo, Japan - April 21, 2003 - Yamanouchi Pharmaceutical Co., Ltd. (President: Toichi Takenaka) agreed with Chugai Pharmaceutical Co., Ltd. (President: Osamu Nagayama) that an agreement between the two companies regarding the marketing of the oral hypoglycemic agent Euglucon Tablet (generic name: glibenclamide) and the cardiotonic glycoside Lanirapid Tablet (generic name: metildigoxin) be terminated on September 30, 2003 upon its expiration. The marketing of the two drugs will be transferred from Yamanouchi to Chugai on October 1, 2003. Combined sales of the two drugs by Yamanouchi in the fiscal year ended March 2002 totaled about 8 billion yen.

Drugs to be transferred from Yamanouchi to Chugai

Euglucon Tablets 1.25mg and 2.5mg
Lanirapid Tablets 0.05mg and 0.1mg